Renaissance Capital logo

Gene therapy biotech Affinia Therapeutics withdraws $100 million IPO

December 2, 2022

Affinia Therapeutics, a preclinical biotech developing novel gene therapies for rare diseases and cancer, withdrew its plans for an initial public offering on Friday. It originally filed in January 2022 with a proposed deal size of $100 million. The company had not updated its prospectus since then.

The Waltham, MA-based company was founded in 2019 and booked $8 million in collaboration revenue for the 12 months ended September 30, 2021. It had planned to list on the Nasdaq under the symbol AFTX. Goldman Sachs, Jefferies, Piper Sandler, and Chardan Capital Markets were set to be the joint bookrunners on the deal.